Cannabis and Restless Legs Syndrome
What the evidence actually says about using cannabis for RLS — separating small case series from genuine clinical findings.
RLS is one of the few conditions where cannabis has surprisingly consistent patient-reported benefit — but 'consistent' here means a handful of small surveys and one case series, not real trials. There are zero randomized controlled trials of cannabis for RLS as of 2024. If standard treatments (dopamine agonists, gabapentinoids, iron) aren't working or are causing augmentation, cannabis is a plausible thing to discuss with a sleep neurologist. It is not a first-line option, and the evidence is thinner than enthusiasts suggest.
Not medical advice
This article is not medical advice. RLS is often a symptom of an underlying issue — iron deficiency, kidney disease, pregnancy, or a medication side effect — that needs a proper workup. If you have restless legs symptoms, see a clinician before self-treating with cannabis or anything else. Cannabis can interact with sedatives, antidepressants, and dopaminergic drugs commonly used for RLS.
Plain-language summary
Restless legs syndrome (RLS) is a neurological condition where you get an uncomfortable, hard-to-describe urge to move your legs, usually in the evening or at night, relieved temporarily by movement. It wrecks sleep. Standard treatments include iron supplementation when ferritin is low, gabapentin/pregabalin, dopamine agonists (pramipexole, ropinirole, rotigotine), and in severe cases low-dose opioids [1].
A small number of patients report that cannabis — usually smoked or vaporized flower — relieves their symptoms, sometimes dramatically. The published evidence consists of one French case series of six patients [2], a few survey studies [3][4], and scattered case reports. There are no randomized controlled trials. So we can say cannabis might help some people with RLS, but we cannot say how often, for how long, at what dose, or in comparison to anything else.
What probably works (in RLS generally — not cannabis)
Before getting to cannabis, the things with actual strong evidence for RLS are:
- Iron repletion when serum ferritin is below ~75 ng/mL Strong evidence [1][5]
- Alpha-2-delta ligands (gabapentin enacarbil, pregabalin) Strong evidence [1]
- Dopamine agonists, though long-term use causes augmentation — a worsening of symptoms over time Strong evidence [1][6]
- Low-dose opioids (methadone, oxycodone) for refractory cases Strong evidence [1]
If you have not had a ferritin level checked, that is the first conversation to have with your doctor.
What might work: cannabis evidence
The most-cited paper is Megelin and Ghorayeb (2017), a case series of six RLS patients who used cannabis Weak / limited [2]. All six reported total or near-total symptom relief. Five smoked it; one used CBD oil. This is six patients, no control group, no blinding, self-selected.
A 2020 Israeli survey by Ghorayeb of patients in an online RLS community found that of those who had tried cannabis, most reported improvement in symptoms and sleep Weak / limited [3]. This is survey data with strong selection bias — people who got no benefit are less likely to be in the cannabis discussion in the first place.
A 2023 review in Sleep Medicine Reviews concluded that evidence is limited to case reports and uncontrolled studies, and called for randomized trials Weak / limited [4].
What we can reasonably say: a subset of RLS patients get meaningful subjective relief from cannabis, particularly inhaled forms with rapid onset that can be timed to evening symptoms. Whether this is a direct effect on the underlying RLS pathology, a sleep-promoting effect, an anxiolytic effect, or placebo cannot be untangled from current data.
What doesn't work / weak evidence
- CBD alone for RLS: one patient in the Megelin case series used CBD oil with reported benefit, but there is no other published evidence specifically for CBD in RLS No data.
- Topical cannabis for RLS: no published data No data. RLS is a central nervous system disorder; topicals are unlikely to reach the relevant receptors.
- Indica vs. sativa labeling: marketing folklore. The indica/sativa distinction does not reliably predict chemical content or effects Disputed. See Indica vs Sativa.
- Specific 'RLS strains': dispensary marketing, not evidence No data.
- Cannabis reducing periodic limb movements of sleep (PLMS) on polysomnography: no controlled data exists No data. Patients report symptom relief; we don't know if the objective movement disorder is changing.
What we don't know
Almost everything that matters for a clinical recommendation:
- Whether cannabis works better than placebo in a blinded trial.
- Which cannabinoids matter (THC, CBD, both, minor cannabinoids).
- Effective dose ranges.
- Whether tolerance develops, as it does with dopamine agonists (augmentation).
- Whether daily cannabis use causes a rebound or withdrawal-related worsening of RLS — this is biologically plausible and unstudied.
- Interactions with standard RLS drugs.
- Effects in pregnancy-related RLS (cannabis should be avoided in pregnancy regardless Strong evidence [7]).
Comparison with standard treatments
| Treatment | Evidence quality | Onset | Main downside | |---|---|---|---| | Iron (if deficient) | Strong | Weeks | Slow; only works if ferritin is low | | Gabapentin enacarbil / pregabalin | Strong | Days | Sedation, weight gain, dizziness | | Dopamine agonists | Strong short-term | Days | Augmentation with long-term use; impulse-control disorders | | Low-dose opioids | Strong (refractory cases) | Hours | Dependence, regulatory barriers | | Cannabis | Weak (case series, surveys) | Minutes (inhaled) | Cognitive effects, dependence potential, no long-term data |
None of the head-to-head comparisons have been done. Patient anecdotes that cannabis works 'better than ropinirole' are interesting but not evidence in the formal sense.
Risks and practical considerations
If you and your clinician decide to try cannabis for RLS:
- Inhaled forms (vaporized flower) have the fastest onset and are easiest to titrate for evening symptoms. Edibles are slow and unpredictable — a bad match for a symptom that arrives at bedtime.
- Start low. RLS patients are often older, often on other CNS-active drugs, and dose-finding matters.
- Watch for interactions: cannabis can amplify sedation from gabapentinoids, opioids, and benzodiazepines.
- Daily use risks: cannabis use disorder is real (affects roughly 1 in 10 users, higher in daily users) Strong evidence [8]. Heavy use disrupts sleep architecture, especially REM sleep, and abrupt cessation can cause rebound insomnia — which is exactly what RLS patients are trying to avoid.
- Driving: residual cognitive impairment the next morning is possible, especially with edibles or high doses.
- Don't replace a workup: cannabis does not fix iron deficiency, kidney disease, or neuropathy mimicking RLS.
The honest summary: cannabis for RLS is a reasonable thing to discuss with a sleep specialist if standard treatments have failed or caused augmentation. It is not a first-line treatment, and anyone telling you the evidence is strong is overselling six patients.
Sources
- Peer-reviewed Silber MH, Buchfuhrer MJ, Earley CJ, et al. The Management of Restless Legs Syndrome: An Updated Algorithm. Mayo Clinic Proceedings. 2021;96(7):1921-1937.
- Peer-reviewed Megelin T, Ghorayeb I. Cannabis for restless legs syndrome: a report of six patients. Sleep Medicine. 2017;36:182-183.
- Peer-reviewed Ghorayeb I. More evidence of cannabis efficacy in restless legs syndrome. Sleep and Breathing. 2020;24(1):277-279.
- Peer-reviewed Samaha D, Kandiah T, Zimmerman D, Burns KD. Cannabis use in restless legs syndrome: a scoping review. Sleep Medicine Reviews. 2023.
- Peer-reviewed Allen RP, Picchietti DL, Auerbach M, et al. Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease. Sleep Medicine. 2018;41:27-44.
- Peer-reviewed Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation. Sleep Medicine. 2016;21:1-11.
- Government American College of Obstetricians and Gynecologists. Committee Opinion No. 722: Marijuana Use During Pregnancy and Lactation. 2017 (reaffirmed). ↗
- Peer-reviewed Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013. JAMA Psychiatry. 2015;72(12):1235-1242.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Chronic Pain — What the evidence actually says about cannabis for long-term pain, separated from the mark...
- Cannabis Use Disorder — A real DSM-5 diagnosis affecting roughly 1 in 5 regular users, with modest but growing evi...